Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
Novel pharmacological advances in individuals with OSA and obesity have shown promise in cardiometabolic disease control. Longitudinal follow-up to monitor the efficacy and adverse effects of incretin therapies, and further comparison studies with PAP therapy, are warranted.
Authors
- Karen C. McCowen (ORCID: https://orcid.org/0000-0002-2743-0022)
- Mizuho S. Mimoto (ORCID: https://orcid.org/0000-0002-4624-7645)
- Danielle A. D’Annibale
- Atul Malhotra (ORCID: https://orcid.org/0000-0002-7021-9302)
Institutions
- Diabetes Australia (AU)
- University of California San Diego (US)
- Pulmonary and Critical Care Associates (US)
- Institute of Nutrition, Metabolism and Diabetes (CA)
Publication Details
- Journal
- Current Opinion in Pulmonary Medicine
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1097/mcp.0000000000001208
- Citations
- 3
- Primary Topic
- Obstructive Sleep Apnea Research
- Type
- article
- Field-Weighted Citation Impact
- 3.49
Funders
- Eli Lilly and Company
- LivaNova